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Abstract
Biallelic MFSD8 variants are an established cause of severe late-infantile subtype of
neuronal ceroid lipofuscinosis (v-LINCL), a severe lysosomal storage disorder, but
have also been associated with nonsyndromic adult-onset maculopathy. Here, we
functionally characterized two novel MFSD8 variants found in a child with juvenile
isolated maculopathy, in order to establish a refined prognosis. ABCA4 locus res-
equencing was followed by the analysis of other inherited retinal disease genes by
whole exome sequencing (WES). Minigene assays and cDNA sequencing were used
to assess the effect of a novel MFSD8 splice variant. MFSD8 expression was quantified
with qPCR and overexpression studies were analyzed by immunoblotting. Transmission
electron microscopy (TEM) was performed on a skin biopsy and ophthalmological and
neurological re-examinations were conducted. WES revealed two novel MFSD8 vari-
ants: c.[590del];[439+3A>C] p.[Gly197Valfs*2];[Ile67Glufs*3]. Characterization of the
c.439+3A>C variant via splice assays showed exon-skipping (p.Ile67Glufs*3), while
overexpression studies of the corresponding protein indicated expression of a trun-
cated polypeptide. In addition, a significantly reduced MFSD8 RNA expression was
noted in patient's lymphocytes. TEM of a skin biopsy revealed typical v-LINCL
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lipopigment inclusions while neurological imaging of the proband displayed subtle cere-
bellar atrophy. Functional characterization demonstrated the pathogenicity of two
novel MFSD8 variants, found in a child with an initial diagnosis of juvenile isolated
maculopathy but likely evolving to v-LINCL with a protracted disease course. Our study
allowed a refined neurological prognosis in the proband and expands the natural
history ofMFSD8-associated disease.
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1 | INTRODUCTION
Isolated macular dystrophies are characterized by degeneration of the
central inner retina. Up to now, isolated maculopathies were found to
be associated with over 26 genes and 2 loci, of which ATP binding
cassette subfamily A member 4 gene (ABCA4) is the most frequently
involved and the Major Facilitator Superfamily Domain containing
Protein-8 gene (MFSD8, encoding CLN7) one of the more recently identi-
fied genes.1-4 The associated phenotype of the latter is characterized by
macular dystrophy with central cone involvement or widespread retinop-
athy. This has been attributed to the combination of hypomorphic and
loss-of-function MFSD8 alleles or biallelic mild MFSD8 alleles.1-3 Biallelic
loss-of-function MFSD8 variants on other hand, display a subtype of
neuronal ceroid lipofuscinosis (NCL), named variant late-infantile NCL
(v-LINCL, CLN7, NCL7), which is a severe lysosomal storage disorder
leading to neurodegeneration.5-7 The first NCL symptoms usually arise
between 2 and 5 years of age and are characterized by epileptic seizures
and developmental regression.8 Ultimately ataxia, myoclonus, and visual
impairment are seen, which are typical features of a progressive NCL
disease leading to premature death. As in other NCL subtypes, accumu-
lation of autofluorescent storage material in neurons and in other cell
types can sometimes be observed, ranging from fingerprint and curvilin-
ear structures to rectilinear profiles.9,10
Here, the female proband presented with an isolated maculopathy
initially diagnosed as atypical Stargardt disease at age 5 and under-
went genetic testing of the entire ABCA4 gene, followed by whole
exome sequencing (WES)-based inherited retinal disease gene panel
testing. Identification of novel MFSD8 variants and their downstream
functional characterization led to ophthalmological and neurological
reassessments, finally allowing refinement of the neurological prognosis
of this proband and expanding the natural history of MFSD8-associated
disease.
2 | MATERIALS AND METHODS
2.1 | Subjects
Legal parental consent was obtained for the study, which was
approved by the institutional ethical committee (B670201525349 and
B670201734438). The proband is a currently 12-year-old Caucasian
female, with nonconsanguineous parents. She was first noted to have
visual problems at age 5, and was originally diagnosed with atypical
Stargardt disease.
2.2 | Clinical assessment of the proband
Ophthalmic examination of the female proband at age 5 included
best-corrected visual acuity (BCVA) measurements, fundus photogra-
phy, and electroretinography (ERG) according to the International
Society for Clinical Electrophysiology of Vision (ISCEV) standards. In
addition, spectral-domain optical coherence tomography (SD-OCT)
and blue light (488 nm) autofluorescence imaging (BAF), Heidelberg
Spectralis HRA+OCT (Heidelberg Engineering, Heidelberg, Germany)
were performed. Ophthalmologic reassessments were undertaken at
ages 8 and 10. In addition, a neurological assessment was performed,
consisting of a clinical neurological examination, electroencephalo-
gram (EEG) and brain magnetic resonance imaging (MRI).
2.3 | Molecular genetic analyses
EDTA blood samples were obtained from the proband, the unaffected
parents and five healthy controls. DNA was isolated from peripheral
blood lymphocytes by standard procedures. In addition, short-term
lymphocyte cultures were established for all samples.
2.3.1 | Targeted next-generation sequencing of the
coding region of ABCA4
The coding region of ABCA4 was enriched by PCR amplification of all
coding exons and flanking splice-site sequences, followed by targeted
next-generation sequencing (NGS) as described (MiSeq, Illumina, San
Diego, California).11
2.3.2 | Locus resequencing of ABCA4
A region encompassing the entire ABCA4 gene (chr1:94337885-
94703604, hg19) was enriched using a custom HaloPlex Target enrich-
ment kit (Agilent Technologies, Belgium), followed by NGS (MiSeq,
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Illumina, San Diego, California). Data were analyzed as described
previously.12
2.3.3 | Whole exome sequencing
To enrich and sequence the exome, the SureSelectXT HumanAllExon
V5+UTRs kit (Agilent, Santa Clara, California) and NextSeq 500
(Illumina, San Diego, California) were used. Data were mapped with the
CLC Bio software (CLC Bio, Qiagen, Hilden, Germany) and analyzed
using the Ingenuity Variant Analysis pipeline (Qiagen, Hilden, Germany).
Keywords used for filtering were Stargardt disease, blindness, and mac-
ular degeneration. Sanger sequencing was used to confirm and assess
segregation of the filtered variants, in both the proband and the parents
(Tables S1 and S2).
2.3.4 | RPGR ORF15 testing
Whole exome sequencing-based testing was complemented with
RPGR ORF15 testing. Targeted enrichment of ORF15 amplicons using
PCR was followed by library preparation (Nextera XT, Illumina, San
Diego, California) and NGS (Miseq, Illumina, San Diego, California).
2.4 | Transcript analyses
2.4.1 | cDNA sequencing
Short-term lymphocyte cultures were treated either with or without
puromycin as a nonsense-mediated decay inhibitor (200 μg/ml; Sigma-
Aldrich, St. Louis, Missouri) 5 hours before RNA extraction. RNA isola-
tion was followed by DNase treatment (Heat & Run gDNA removal kit,
ArticZymes, Tromsø, Norway) and cDNA synthesis (iScript cDNA syn-
thesis kit, BioRad, Hercules, California). After PCR, RT-PCR products
were loaded onto the capillary labchip (Caliper, Hopkinton, Massachu-
setts) and Sanger sequenced (ABI3730XL, Genetic analyser; Applied
Biosystems, Foster City, California). The PCR primers can be found in
Table S3.
2.4.2 | Expression analysis
Quantitative polymerase chain reaction (qPCR; LC480, Roche, Basel,
Switzerland) was used to compare RNA expression levels of MFSD8
between the proband, the carrier parents and five healthy controls.
Primers can be found in Table S4. qBasePlus (Biogazelle, Zwijnaarde,
Belgium) was used for data-analysis, normalization was performed using
two reference genes (YWAZ and GAPDH).
2.5 | In vitro splice assays
A genomic segment of MFSD8 spanning exon 5 (hg19,
chr4:128864292-128865864) was amplified from patient DNA using
primers with NotI and BamHI recognition sequences (Table S5). PCR
products were cloned into the pCR2.1 plasmid (Invitrogen-Life Tech-
nologies, Carlsbad, California). Wild type (WT) and mutant inserts
were excised by digestion and subcloned into digested pSPL3_2096
(Invitrogen-Life Technologies, Carlsbad, California). HEK293T
cells were transfected with pSPL3-MFSD8 constructs using
Lipofectamine (Invitrogen-Life Technologies, Carlsbad, California).
Total RNA was extracted after 24 hours (peqGOLD Total RNA Kit,
VWR, Radnor, Pennsylvania) and reversely transcribed (Transcriptor
High Fidelity cDNA Synthesis Kit, Roche Applied Science, Penzberg,
Germany). The cDNA was PCR amplified with pSPL3 exon
primers and Sanger sequenced (Applied Biosystems, Foster City,
California).
2.6 | In vitro overexpression studies
2.6.1 | Cloning of 3xFLAG CLN7 expression
constructs
A cDNA construct with a triple FLAG tag fused to the N-terminus of
CLN7 was generated by amplifying human MFSD8 cDNA (NM_152778,
RZPD clone IRATp970E0532D6; imaGenes, Berlin, Germany) using
primers 3xFLAG pCMV10-CLN7 F/R and cloning this into the p3xFLAG-
CMV10 vector (Sigma-Aldrich, St. Louis, Missouri). The cDNA coding for
human mutant CLN7 Ile67Glufs*3 was purchased (Source BioScience,
Nottingham, UK) and amplified. Primers can be found in Table S6. PCR
products were separated and purified from agarose gels, cleaved with
restriction enzymes and cloned into the p3xFLAG-CMV10 expression
vector (Sigma-Aldrich, St. Louis, Missouri) generating the mutant 3xFLAG
p.Ile67Glufs*3.
2.6.2 | Western blot analysis
HEK293T cells were transiently transfected using Jet Pei reagent
(Polyplus Transfection, Illkrich, France) with either 3xFLAG-CLN7,
3xFLAG-p.Ile67Glufs*3 or a mock construct as control and harvested
24 hours after the start of transfection. Preparation of postnuclear
supernatants and total membrane fractions was performed as described
previously.13 Membrane pellets were homogenized in extraction buffer
containing 50 mM Tris-HCl, pH 7.5, 1% TX-100 (v/v), 1 mM EDTA and
inhibitor cocktail and incubated on ice for 30 minutes. Immunoblot ana-
lyses were performed using anti-FLAG and anti-α-tubulin antibodies
(Sigma, St. Louis, Missouri).
2.7 | Transmission electron microscopy
A skin biopsy from the patient was explanted and incubated at 37C
in a humidified atmosphere containing 5% CO2. Part of this biopsy
was fixed and processed for transmission electron microscopy (TEM),
using standard techniques: fixation in 2.5% glutaraldehyde and 4%
formaldehyde, postfixation in osmium tetroxide, embedding in ara-
ldite, staining with uranyl acetate and lead citrate. An FEI CM10 trans-
mission electron microscope was used at 60 kV.
BAUWENS ET AL. 3
3 | RESULTS
3.1 | Identification of biallelic novel MFSD8 variants
Given the initial diagnosis of atypical Stargardt disease in the female
proband at age 5, targeted testing of ABCA4 was conducted. Sequenc-
ing of the coding region of ABCA4 and of the entire ABCA4 locus rev-
ealed one heterozygous ABCA4 variant c.3113C>T; p.(Ala1038Val).
No other (likely) pathogenic coding or noncoding ABCA4 variants
including copy number variants were identified. Subsequently, WES
was performed in the proband and data were filtered in order to
select variants in known retinopathy genes, assuming an autosomal
recessive inheritance mode (Table S2). WES was complemented with
screening of ORF15 of the RPGR gene, which was negative. Two
novel heterozygous MFSD8 variants were identified in the proband:
c.590del and c.439+3A>C. Both unaffected parents were shown to
be heterozygous carrier of anMFSD8 variant. They were not observed
in the NCL database containing all published NCL variants (http://
www.ucl.ac.uk/ncl/cln7.shtml) nor in dbSNP (http://www.ncbi.nlm.
nih.gov/SNP/), 1000Genomes (http://www.1000genomes.org/),
gnomAD (http://gnomad.broadinstitute.org/), or GoNL (http://www.
nlgenome.nl/). Only the c.590del variant was found in the ExAC
browser (ALL: 0.00082%, SAS: 0.0061%). The c.590del variant,
located in exon 7, has the same deleterious prediction on protein level
(p.(Gly197Valfs*2)) as the known pathogenic MFSD8 c.588del variant.
3.2 | Characterization of the novel MFSD8 variant
c.439+3A>C
3.2.1 | Splicing assessment
The different splice annotations of the c.439+3A>C variant pointed
toward a subtle weakening of the donor site of exon 5. A minigene
assay revealed that this variant leads to a skip of exon 5 (241 bp) at
the RNA level in all resulting transcripts, as opposed to the WT situa-
tion, where exon 5 skipping is seen in a smaller fraction of the tran-
script (Figure 1). This out-of-frame exon-skip was confirmed on
lymphocyte cDNA from the proband and the carrier mother while no
exon-skipping could be observed in the noncarrier father or control
(Figure 2A). Contrary to the minigene results, no endogenous exon
F IGURE 1 TheMFSD8 variant c.439+3A>C decreases the strength of the canonical donor site of exon 5, leading to a skip of exon 5, here
shown by a minigene assay. The minigene vector pSPL3, containing two HIV-TAT exons (TAT1, TAT2) flanking the insert and containing the
RT-PCR primer sequences was used. A, RT-PCR products were loaded on gel. MUT (1): RT-PCR product produced by mutant construct;
c.439+3C, WT (1 and 2): RT-PCR products produced by wild type construct; c.439+3A, MQ: milliQ, RT-PCR product of a no-template control
RT-PCR reaction. B, Sanger sequencing profiles of the different RT-PCR products (1 and 2) confirms skipping of exon 5 [Colour figure can be
viewed at wileyonlinelibrary.com]
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5 skipping was observed in noncarriers. Next, the combined and indi-
vidual effects of both variants on MFSD8 expression was assessed
using qPCR on lymphocyte cDNA of the proband, the carrier parents
and five controls. A strong reduction of MFSD8 mRNA expression was
seen in the proband and her carrier parents as compared to the con-
trols, with the strongest reduction observed in the proband with
biallelic MFSD8 variants (Figure 2B-C).
3.2.2 | Overexpression studies
In order to study the effect of the c.439+3A>C variant at the protein
level, overexpression studies with the truncated CLN7 protein fused
to an N-terminal triple FLAG tag (3xFLAG p.Ile67Glufs*3) were per-
formed in HEK293T cells, followed by FLAG immunoblotting of mem-
brane fractions (Figure 3). In 3xFLAG CLN7 expressing HEK293T
F IGURE 2 A, Lymphocyte cDNA
derived from both patient (P) and parents
(M: mother and F: father) confirms the
exon-skip in the patient and carrier
mother. This was seen with (+) and
without puromycin (−) supplementation.
The normal cDNA PCR product,
containing exon 5, is 341 bp in size, while
the exon 5 loss created a product that is
241 bp smaller. B, The normalized
expression profiles of patient (P) and both
parents (F and M) are severely reduced
when compared to controls (C1-C5). C,
MFSD8 mRNA expression levels in the
patient are higher with puromycin (+)
addition. C, negative control, NTC, no-
template control; SEM, standard error of
the mean
F IGURE 3 A, The novelMFSD8
variant c.439+3A>C leads to an exon
5 skip, resulting in a truncated protein
(p.Ile67Glufs*3). A full length CLN7
protein contains 12 transmembrane
domains, the truncated protein
p.Ile67Glufs*3 stops within
transmembrane domain 2. B, Western
blot results of overexpression studies
(performed in triplicate). Membrane
fractions (120 μg protein) were analyzed
by FLAG immunoblotting. Αlpha-tubulin
Western blot was performed to control
equal loading. Positions of the molecular
mass markers are indicated. In extracts
from 3xFLAG CLN7 expressing HEK293T
cells, the full length CLN7 as well as the
cleaved N-terminal fragment could be
detected, here visible as two bands. In
3xFLAG p.Ile67Glufs*3 expressing cells, a
truncated 15 kDa CLN7 protein could be
detected. The bar diagram represents
relative expression levels of wild type
(black bar) and mutant p.Ile67Glufs*3
(gray bar) normalized to the levels of
α-tubulin from three independent
transfections (*p < .05)
BAUWENS ET AL. 5
cells, the full length CLN7 as well as the cleaved N-terminal fragment
were detected, in contrast to 3xFLAG p.Ile67Glufs*3 expressing cells
where a truncated 15 kDa CLN7 protein was detected.14 These data
suggest that the truncated CLN7 polypeptide is expressed, albeit at
lower levels compared to WT CLN7 protein and that it is detectable
in membrane fractions. Based on previously published results of trun-
cated CLN7 protein, it can be predicted that Cln7p.Ile67Glufs*3 is
integrated into membranes but most likely is retained in the endoplas-
mic reticulum.14
3.3 | Ultrastructural features
Transmission electron microscopy revealed characteristic membrane-
bounded inclusions in different cell types of the skin. In secretory cells
of the eccrine sweat glands and blood vessels (endothelial and smooth
muscle cells) many pleomorphic inclusions (1-2 μm diameter), could be
particularly noted, showing mixed rectilinear, curvilinear, and finger-
print lamellar profiles (Figure 4). Some of the inclusions displayed a
more pseudovacuolar aspect (2-3 μm diameter).
3.4 | Clinical neurological and ophthalmological
assessments
3.4.1 | Ophthalmological assessment
The patient was initially referred with a diagnosis of Stargardt disease
at the age of five. Six months prior to this first visit a subnormal BCVA
was noted. BCVA was measured at a Snellen equivalent at 0.13 in
both eyes, without correction. Fundus examination showed central
macular abnormalities in keeping with outer retinal atrophy. No fish-
tail flecks typical of Stargardt disease were observed (Figure 5A-C).
OCT of the macula at age 5 years showed selective thinning of the
outer retinal layers, more pronounced of those representing the pho-
toreceptors. This area of atrophy was generally broader than what is
typical seen at an early stage Stargardt.
Three years later, at age 8, BCVA had decreased to 0.07 in both
eyes. Funduscopy showed expansion of the central macular atrophic
area surrounded by a hyperautofluorescent ring on blue light auto-
fluorescence imaging (Figure 5D-F). A full-field flash electroretinogram
(ERG) at both ages was in keeping with a generalized rod-cone dystrophy
F IGURE 4 Transmission electron
microscopy images taken from a skin
biopsy of the proband (scalebar: 1 μm).
A, Inclusions can be seen in an eccrine
sweat gland (enlargement: 14 500×).
B, Detail of image A: membrane-enclosed
inclusion with a heterogeneous aspect;
lamellar profiles (LP), fingerprints (FP,
arrows) and a fat droplet (FD) are visible.
C, Pleomorphic inclusion in an endothelial
cell (blood vessel; enlargement: 27 000×).
D, Detail of C: inclusion with fingerprints
(FP, arrows) and mixed lamellar profiles
(LP; enlargement: 41 000×)
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F IGURE 5 A-C, Ophthalmological assessment at age 5 showed central macular abnormalities, no fishtail flecks were observed. D-F,
Reassessment at age 8 revealed expansion of the central macular atrophic area (right eye). G-I, This expansion was even more widespread at age
10 (right eye). J and K, Optical coherence tomography images taken at age 8 and 10 clearly show the evolution of the atrophy of the outer retinal
area. BAF, blue light; FP, fundus photography; IRR, near-infrared radiation [Colour figure can be viewed at wileyonlinelibrary.com]
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F IGURE 6 A full-field flash ERG at ages 6 and 8 was in keeping with a generalized rod-cone dystrophy with additional post-photoreceptor
involvement as evidenced by a more pronounced reduction of the b-wave than the a-wave in the maximal combined rod-cone response (reduced
b/a-ratio). At age 10, a rapid decline of generalized retinal function is illustrated by complete absence of all retinal responses on full-field flash
ERG. DA, dark-adapted; LA, light-adapted. ERG, electroretinography
F IGURE 7 A-B, MRI images, taken at age 8. Cerebellar atrophy is visible on T1 and T2 weighted images (arrow). C, In addition, subtle atrophy
of the supratentorial cortex can been seen (arrow). MRI, magnetic resonance imaging
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with additional post-photoreceptor involvement as evidenced by a more
pronounced reduction of the b-wave than the a-wave in the maximal
combined rod-cone response (reduced b/a-ratio; Figure 6). Evolution
was very limited between ages 6 and 8. An OCT at age 8 showed that
the area of outer retinal atrophy in the macula had increased, in keeping
with the increase of the funduscopic lesion (Figure 5J).
At age 10, vision was decreased to counting fingers in both eyes,
white light and infrared reflectance fundus photography show further
expansion of the area of macular atrophy (Figure 5G-I). Rapid decline
of generalized retinal function was illustrated by complete absence of
all retinal responses on full-field flash ERG (Figure 6). Also, further
extension of the area of outer retinal atrophy in the macula was visi-
ble on OCT (Figure 5K). Extensive retinopathy is reflected by a less
well-defined hyperautofluorescent ring in central macula, surrounded
by more diffuse hyperautofluorescence within and beyond vascular
arcades, including the retinal midperiphery. Near-infrared reflectance
imaging shows fine vertical striations in the interpapillomacular bun-
dle, as previously described in mid to later stage CLN3-related
maculopathy by Dulz et al.15 These striations are visible on OCT as
fine cobblestone-like abnormalities of the inner limiting membrane.
3.4.2 | Neurological assessment
After the identification of the two MFSD8 variants a neurological inves-
tigation was undertaken. An EEG did not show any clear epileptiformic
discharges, even after intermittent light stimulation. At first glance, the
MRI results were classified as normal. However, upon further inspec-
tion of T2 weighted images, signs of cerebellar atrophy were visible, as
well as mild atrophy of the supratentorial cortex. The cerebellar atrophy
was also visible on T1 weighted sagittal images (Figure 7A-C). Cur-
rently, at age 12, no epileptic seizures or ataxia have occurred.
4 | DISCUSSION
Using WES, we identified two novel MFSD8 variants c.590del p.(Gly197-
Valfs*2) and c.439+3A>C p.(Ile67Glufs*3) in a now 12-year-old proband
with isolated maculopathy, initially diagnosed as atypical Stargardt dis-
ease. Publications by Roosing et al, Khan et al, and Birtel et al revealed
that the combination of a loss-of-function allele with a hypomorphic allele
or homozygosity for a mild allele in MFSD8 might give rise to an isolated
ocular phenotype ranging from localized maculopathy to widespread reti-
nopathy with severe macular involvement or retinitis pigmentosa (RP).1-3
Interestingly, a recent publication by Zare-Abdollahi et al reported for the
first time patients with an isolated maculopathy and with known com-
pound heterozygous and homozygous missense MFSD8 variants, all of
which have previously been solely associated with v-LINCL.4
In contrast to the patient described here, in whom the first visual
problems were noticed at age 5, the reported onset of the symptoms
in these IRD patients occurred in late adolescence or adulthood
(15-46 years) and had a slower progression.
As the majority of the pathogenic variants in the MFSD8 gene
have been associated with the syndromic v-LINCL phenotype, we
were prompted to determine the functional impact and severity of
these novel MFSD8 variants. Based on the predictions at the protein
level, the c.590del variant p.(Gly197Valfs*2), can be considered a
severe mutation. Using a minigene assay and transcript analysis of
lymphocyte RNA, we could establish that the other allele of interest
c.439+3A>C induced skipping of exon 5 -although other aberrant
splicing cannot be ruled out—and is predicted to result in a truncated
protein p.(Ile67Glufs*3). Overexpression studies showed that the
truncated protein was still expressed, but based on previously publi-
shed data it is likely to be retained in the endoplasmic reticulum and
does not reach the lysosomes.14 In addition, the proband has a
reduced mRNA MFSD8 expression profile when compared to healthy
controls and her carrier parents.
The severity of these novel variants seems comparable to the
v-LINCL causing MFSD8 variants (http://www.ucl.ac.uk/ncl/cln7.
shtml). Corresponding with an alternative diagnosis of v-LINCL,
neurological tests including MRI were performed. While the clinical
neurological examination of the proband was normal, brain MRI
showed slight cerebellar atrophy. Currently, at age 12, no epileptic
seizures or ataxia have occurred. The ultrastructural examination of a
skin biopsy of the proband revealed typical mixed lipopigment inclu-
sions in line with the observations in v-LINCL patients.
A report illustrating atypical syndromic disease progression was
published once by Kousi et al.16 They described a patient homozygous
for p.(Ala157Pro), who first reported visual failure as the presenting
symptom at 11 years of age.16 This was followed by motor impair-
ment at age 24, seizures and ataxia at age 25 and 28. Several years
later, mental regression and speech delay could be observed. This case
eventually became chairbound by age 39.
Visual failure is usually one of the more advanced symptoms in
v-LINCL; however, several cases have been reported where visual
failure precedes other symptoms such as ataxia and seizures, compa-
rable to CLN3 mutations that lead to Batten disease. In most of these
patients, the onset of additional symptoms is delayed with 1 or
2 years when compared to other v-LINCL patients, and seizures,
mental regression and ataxia follow on average 2 years after visual
symptoms are first noted.6,7,16,17
At this moment, it is unclear why certainMFSD8 missense variants
act as functional null alleles and give rise to the syndromic early-onset
v-LINCL in a similar fashion as do frameshift variants, while other mis-
sense variants, such as p.Glu336Gln, p.Met454Thr, and p.Arg482Pro
are able to lead to an isolated maculopathy or retinopathy.1-3 A recent
report on known biallelic MFSD8 variants previously described in
v-LINCL but occurring in patients with an isolated maculopathy in this
study raises even more questions and points to possible cis- or trans-
acting modifiers.4 There is no apparent link between the positions of
the affected amino acids in the CLN7 protein (NP_689991.1) and the
presenting symptom or disease progression, although in the latter
case, these v-LINCL-associated variants are located in the last two
exons of the gene. Localization studies have shown that none of the
investigated missense variants interfere with mislocalization of the
protein, but most likely are pathogenic by affecting the correct
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functioning of the protein, for example by aberrant proteolysis
(Thr294Lys located in luminal loop 7 and Pro412Leu located in lumi-
nal loop 9).14
Although CLN7 is ubiquitously expressed, high expression levels
have been seen in specific neuronal cell types and retinal cells, which
is in line with the most severely affected tissues in v-LINCL.13,18-20
MFSD8 transcripts that lack exon 2, exon 7, exons 7 and 8, and exon
11 have been described, but only the 5 kb transcript, consisting of
13 exons seems to be expressed in the brain.5 There is no indication
that mutations in alternatively spliced exons or in surrounding introns
lead to an atypical or notably milder disease course. Alternative tran-
scripts were identified in lymphocytes and fibroblasts of patients and
controls when studying the effect of splice variants near these exons
(eg, c.754+2T-A, c.863+3_4insT, and c.1102G>C).
Recently, Khan et al discussed a synaptic origin of theMFSD8-associ-
ated retinal disease based on the observation that ERG abnormalities
seen in the MFSD8-patients reported are indicative of a post-
phototransduction abnormality and that murine MFSD8 localizes to the
photoreceptor presynaptic terminals in the outer plexiform layer.2 The
ocular phenotype in the patients studied suggests that, of all affected
cell types, macular photoreceptors would be most sensitive to MFSD8
mutations, followed by the extramacular photoreceptors, with cortical
neurons being the most resistant. These observations are in line with
the severity of the affected cell types and disease progression seen in
the patient of this study. Our hypothesis is that in typical v-LINCL
patients, a complete lack or a minimal amount of functional CLN7 pro-
tein leads to a very rapid disease progression where there is hardly any
distinction in the time of onset between the first developing symptoms
and the succeeding disease features. Within some families with several
affected v-LINCL individuals having the same MFSD8 genotype, some
variability can be seen in the age of onset and sequence of symptoms.
In case of residual functional CLN7 protein however, slower disease
progression or even an atypical disease course is seen, with the macula
being first affected and eventually leading to a more widespread reti-
nopathy or even neuronal loss in line with the severity of the MFSD8
pathogenic variants.
In numerous other NCL disorders, similar clinical heterogeneity
was observed.8 A first example is CLN1 disease, were milder CLN1
mutations, giving rise to a phenotype of later onset (late infantile,
juvenile, and adult) compared to the classic infantile disease.21-24 The
correlation between the severity of CLN1 mutations and onset of dis-
ease however is not fully understood, as some patients homozygous
for an apparent milder variant have an earlier onset than patients who
are compound heterozygous for a severe and a mild allele.8 There is
also a spectrum of CLN3-associated phenotypes, ranging from the
syndromic NCL to isolated late onset RP (Wang et al) and protracted
NCL with autophagic myopathy.25-31 Finally, KCTD7 (CLN14) muta-
tions were reported to underlie progressive myoclonic epilepsy and
opsoclonus-myoclonus ataxia-like syndrome.32 Surprisingly, a homo-
zygous missense variant in KCTD7 associated with infantile onset NCL
with vision loss and cognitive and motor regression has also been
reported.32-34
In conclusion, WES-based testing revealed two novel likely patho-
genic MFSD8 variants in a 5-year-old patient manifesting only visual
symptoms at the time of genetic testing. Seven years later, she does
not display clinically apparent neurological symptoms, which is atypi-
cal for classical v-LINCL disease. Apart from the nonsyndromic
MFSD8-associated retinopathies, an atypical disease course of neuro-
logical MFSD8-associated disease has been described once. Based on
the young age of the patient, the functional characterization of the vari-
ants and the typical NCL storage in a skin biopsy, however, we antici-
pate progression to a neurodegenerative NCL-like disorder. Finally, this
study illustrates the power of integrated genomic and functional char-
acterization for precision medicine of a heterogeneous disease, to
refine clinical diagnoses and to anticipate disease progression.
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